Journal Article

Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries

Kazakova, Evgeniya, Lapovok, Ilya, Kirichenko, Alina, Yurovsky, Pavel, Ismatova, Laylo, Pokrovsky, Vadim, Musabaev, Erkin, Rakhimova, Visola, Soliev, Alijon, Nurov, Rustam, Murzakova, Anastasia, Safarova, Aygun, Grigoryan, Trdat, Sarhatyan, Tatevik, Bunas, Anastasia, Ibrahimova, Sabina, Petrosyan, Arshak, Ladnaya, Natalya, Gasich, Elena, Kireev, Dmitry, Saleeva, Daria, Gadirova, Agigat, Glinskaya, Iryna, Lopatukhin, Alexey

2022

Overview

Eastern Europe and Central Asia (EECA) is one of the regions where the HIV epidemic continues to grow at a concerning rate. Antiretroviral therapy (ART) coverage in EECA countries has significantly increased during the last decade, which can lead to an increase in the risk of emergence, transmission, and spread of HIV variants with drug resistance (DR) that cannot be controlled. Because HIV genotyping cannot be performed in these countries, data about HIV DR are limited or unavailable. To monitor circulating HIV-1 genetic variants, assess the prevalence of HIV DR among patients starting antiretroviral therapy, and reveal potential transmission clusters among patients in six EECA countries: Armenia, Azerbaijan, Belarus, Russia, Tajikistan, and Uzbekistan. We analyzed 1071 HIV-1 pol-gene fragment sequences (2253-3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019. HIV Pretreatment DR (PDR) and drug resistance mutation (DRM) prevalence was estimated using the Stanford HIV Resistance Database. The PDR level was interpreted according to the WHO standard PDR survey protocols. HIV-1 subtypes were determined using the Stanford HIV Resistance Database and subsequently confirmed by phylogenetic analysis. Transmission clusters were determined using Cluster Picker. Analyses of HIV subtypes showed that EECA, in general, has the same HIV genetic variants of sub-subtype A6, CRF63_02A1, and subtype B, with different frequencies and representation for each country. The prevalence of PDR to any drug class was 2.8% in Uzbekistan, 4.2% in Azerbaijan, 4.5% in Russia, 9.2% in Armenia, 13.9% in Belarus, and 16.7% in Tajikistan. PDR to protease inhibitors (PIs) was not detected in any country. PDR to nucleoside reverse-transcriptase inhibitors (NRTIs) was not detected among patients in Azerbaijan, and was relatively low in other countries, with the highest prevalence in Tajikistan (5.6%). The prevalence of PDR to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) was the lowest in Uzbekistan (2.8%) and reached 11.1% and 11.4% in Tajikistan and Belarus, respectively. Genetic transmission network analyses identified 226/1071 (21.1%) linked individuals, forming 93 transmission clusters mainly containing two or three sequences. We found that the time since HIV diagnosis in clustered patients was significantly shorter than that in unclustered patients (1.26 years vs 2.74 years). Additionally, the K103N/S mutation was mainly observed in clustered sequences (6.2% vs 2.8%). Our study demonstrated different PDR prevalence rates and DR dynamics in six EECA countries, with worrying levels of PDR in Tajikistan and Belarus, where prevalence exceeded the 10% threshold recommended by the WHO for immediate public health action. Because DR testing for clinical purposes is not common in EECA, it is currently extremely important to conduct surveillance of HIV DR in EECA due to the increased ART coverage in this region.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Acquired immune deficiency syndrome / Adult / AIDS / Anti-HIV Agents - pharmacology / Anti-HIV Agents - therapeutic use / Antiretroviral agents / Antiretroviral drugs / Antiretroviral therapy / Armenia - epidemiology / Asia, Central - epidemiology / Azerbaijan - epidemiology / Biology and Life Sciences / Cluster analysis / Disease transmission / Drug resistance / Drug Resistance, Viral - genetics / Epidemics / Epidemiology / Europe, Eastern - epidemiology / Female / Gene sequencing / Genetic analysis / Genetic aspects / Genetic diversity / Genetic variance / Genotype / Genotyping / GLP-1 receptor agonists / HIV / HIV (Viruses) / HIV Infections - drug therapy / HIV Infections - epidemiology / HIV Infections - transmission / HIV Infections - virology / HIV-1 - drug effects / HIV-1 - genetics / Human immunodeficiency virus / Humans / Identification and classification / Male / Medicine and health sciences / Middle Aged / Mutation / Non-nucleoside reverse transcriptase inhibitors / Nucleoside reverse transcriptase inhibitors / Patients / People and Places / Phylogeny / Prevalence / Protease inhibitors / Proteinase inhibitors / Public health / Republic of Belarus - epidemiology / Russia - epidemiology / Statistics / Tajikistan - epidemiology / Uzbekistan - epidemiology / Young Adult